InMed Pharmaceuticals (INM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InMed Pharmaceuticals has published a promising study showcasing the anti-inflammatory effects of cannabinol (CBN) on skin diseases, highlighting its potential for therapeutic and cosmetic applications. This research emphasizes CBN’s ability to modulate the endocannabinoid system and regulate inflammation in conditions such as psoriasis and dermatitis. The findings could pave the way for new treatments targeting inflammation in various diseases.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.